Market Overview

From Biogen Call: Eloctate Could Be Facing Potential Approval Delay

Share:
Related BIIB
Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts
Leerink Is Back On Board The Biotech Train
Healthcare ratings roundup (Seeking Alpha)

Posted-In: News FDA

 

Related Articles (BIIB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters